2 days ago
1
janiecbros/E+ via Getty Images
- Personalis (NASDAQ:PSNL) has shared new results from a late-stage trial conducted by AstraZeneca (AZN) focused on lung cancer.
- The results indicate that Personalis’ advanced molecular residual disease test, known as NeXT Personal, effectively predicts outcomes for patients with stage II-IIIb, EGFR-mutated non-small cell lung
English (US) ·